MVM Partners LLP has partially divested its stake in Ambio Holdings, Inc. (“Ambio”) a global leader in peptide manufacturing and development to The Carlyle Group (“Carlyle”) (NASDAQ: CG). Equity for the transaction comes from Carlyle Asia Partners V, its flagship $6.55 billion Asia fund that makes buyout and strategic investments across a wide range of sectors in Asia Pacific. MVM remains a significant shareholder of Ambio and maintains representation on the company’s Board of Directors.

Dr. Eric Bednarski, Partner of MVM, said, “MVM was the first institutional investor in Ambio. Since our investment in November 2014, Ambio has increased revenue more than 350% and built a highly profitable business. We are pleased to add Carlyle as an institutional partner and will continue working with management to drive future success of the company.”

Ambio is a primary supplier of complex peptide active pharmaceutical ingredients to the global pharmaceutical industry and its customers include many of the largest branded, generic and biotechnology companies. Ambio also has a rich and growing pipeline of proprietary drug development programs for generic versions of the world’s best-selling peptide drugs. The company is headquartered in North Augusta, South Carolina, and has manufacturing operations in Shanghai, China.

Latest news

MVM invests in Nalu Medical
February 17, 2022

CARLSBAD, Calif. (PRWEB) February 17, 2022 Nalu Medical, Inc. (“Nalu”), a private company focused on innovative and minimally invasive solutions for […]

Clarivate acquires Patient Connect
December 22, 2021

 Clarivate Plc (NYSE:CLVT), a global leader in providing trusted information and insights to accelerate the pace of innovation, today announced that […]

MVM invests in Vero Biotech
December 15, 2021

VERO Biotech Inc., a fast-growing commercial business dedicated to improving the lives of patients through innovative technologies, today announced the […]

MVM Invests In Optinose
November 18, 2021

MVM invested $20 million in Optinose. Optinose markets XHANCE, an innovative drug delivery system that delivers steroids high and deep […]

Paragon 28, Inc. Announces Pricing of Initial Public Offering
October 15, 2021

ENGLEWOOD, Colo., Oct. 15, 2021 /PRNewswire/ — Paragon 28, Inc. (NYSE: FNA) (“PARAGON”), a leading medical device company exclusively focused on the foot and […]

MVM invests in InBrace
September 8, 2021

MVM invested $15 million in InBrace. InBrace is an orthodontic company that created the novel SmartwireTM, a new category in […]

Valneva Announces Positive Phase 3 Pivotal Results for its Single-Shot Chikungunya Vaccine Candidate
August 6, 2021

Saint Herblain (France), August 5, 2021 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company focused on the […]

Vertos mild® Patients Demonstrate Durable 5 Year Outcomes
May 18, 2021

Most Minimally Invasive Lumbar Decompression (mild®) providers are very familiar with the 1-year study conducted by Nagy Mekhail, MD, PhD […]

Valneva Announces the Pricing of its Initial Public Offering on Nasdaq
May 11, 2021

Saint-Herblain (France), May 6, 2021  – Valneva SE, a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for […]

eXmoor pharma secures £12m ($17m) from healthcare investment firm MVM marking milestone towards significant expansion plans
March 16, 2021

eXmoor, the expert cell and gene therapy (CGT) services company (Bristol, England), has announced an initial investment of £12m ($17m) […]